Stocktoria
BioXcel Therapeutics, Inc. BTAI
BioXcel Therapeutics, Inc. statistics & valuation
Market cap$40.4M
P / S63.0×
Net margin-10887.4%
FCF margin-8974.3%
Net debt$81.2M
Enterprise value USD$121.6M
Earnings yield EBIT/EV-41.5%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -7860.0% | -2967.6% | -12448.0% | -42572.0% | — | — | — | — | — |
| Net margin | -10887.4% | -2630.1% | -12974.9% | -44201.9% | — | — | — | — | — |
| FCF margin | -8974.3% | -3178.6% | -11233.8% | -36128.0% | — | — | — | — | — |
| Return on assets | -155.6% | -155.5% | -242.9% | -80.5% | -44.7% | -37.4% | -90.6% | -44.2% | -335.0% |
| Return on equity | 73.2% | 64.0% | 316.9% | -215.9% | -48.2% | -39.8% | -122.6% | -49.6% | 462.2% |
| Debt / equity | -1.15× | -1.10× | -1.78× | 1.21× | — | — | — | — | — |
| Current ratio | 0.83 | 1.68 | 2.65 | 6.17 | 14.21 | 18.33 | 4.03 | 9.26 | 0.38 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.